Ade Dharmawan
Departemen Mikrobiologi Klinik, Fakultas Kedokteran Dan Ilmu Kesehatan, Universitas Kristen Krida Wacana, Jakarta, Indonesia

Published : 32 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Jurnal MedScientiae

Efektivitas Ceftazidime-Avibactam terhadap Bakteri Gram Negatif Penghasil Enzim Karbapenemase Ade Dharmawan; Nicolas Layanto
Jurnal MedScientiae Volume 1 No 01 : Mei - Agustus 2022
Publisher : Fakultas Kedokteran dan Ilmu Kesehatan Ukrida

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (372.965 KB) | DOI: 10.36452/jmedscientiae.vi.2453

Abstract

Antibiotic therapy is a major concern in the health sector. There is an increase in the resistance of gram-negative bacteria that produce carbapenemase enzymes to certain antibiotics, especially the β-lactam group, thus creating a new challenge for the health world to find stronger antibiotics to fight the resistance of these gram-negative bacteria. Currently, there are several new antibiotics that have been approved as treatment options, such as Ceftazidime-Avibactam. It is hoped that this new treatment can be an option, especially for gram-negative bacteria that produce carbapenemase enzymes.  
Pengaruh Pemberian Probiotik pada Infeksi Clostridium Difficile Ade Dharmawan; Dhimas Garin Dewa Agista; Sinsanta Sinsanta; Nicolas Layanto; Deby Deby
Jurnal MedScientiae Volume 1 No 2 : September - Desember 2022
Publisher : Fakultas Kedokteran dan Ilmu Kesehatan Ukrida

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (641.716 KB) | DOI: 10.36452/jmedscientiae.v1i2.2567

Abstract

Clostridium difficile (C. difficile) is a gram-positive, anaerobic, spore-forming bacterium, and is an important pathogen in antibiotic-associated diarrhea. These bacteria are normal flora in the human digestive tract but can become pathogenic and form toxins consisting of 2, namely toxin A and toxin B. Due to antibiotics including risk factors for C. difficile infection (CDI), the treatment that can be given is probiotics. Probiotics may be effective in the prevention and treatment of CDI in several ways: alteration of gut flora, enhancement of antimicrobial activity, and as immunomodulators. The effect of probiotics, the method of administration, and the varying duration of administration make probiotics unable to be used as a therapy for C. difficile infection. However, probiotics can still be an option for adjuvant therapy in the treatment of CDI.